BOLT

BOLT
Enrolling By Invitation
99 years or below
All
Phase N/A
12 participants needed
1 Location

Brief description of study

The objective of this study is to demonstrate the safety and efficacy of the Indigo Aspiration system for percutaneous mechanical thrombectomy in a population presenting with obstruction due to deep vein thrombosis (DVT) who are eligible for treatment.

Detailed description of study

The participants will have a mechanical aspiration thrombectomy procedure that removes the blood clot from their body using the Indigo Aspiration System (study device). 

Approximately 290 participants from up to 50 hospitals in the United States will be participating in this study. This study will last approximately two years. 

Before the participants are treated for their DVT, the hospital staff will perform routine tests and procedures to evaluate the severity of the DVT and the participants’ general state of health. Imaging tests will be done to identify and locate the blood clots. Additionally, the doctor will evaluate the state of the DVT and how it affects the participants’ quality of life before treatment. 

Post procedure, participants will be monitored according to the study doctor’s routine care. Additional examinations, questionnaires, testing, and imaging may be done. 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

Inclusion

  • Unilateral lower extremity DVT occlusion involving iliac and/or common femoral veins, including patients with extension of clot into the contralateral common iliac vein

  • Acute thrombotic or thromboembolic occlusion with symptom duration of 14 days or less at presentation

  • Frontline treatment with Indigo Aspiration System in the target venous segment per Investigator decision

Exclusion

  • Prior stent in target venous segment

  • Treatment of index DVT with thrombolytics within 14 days prior to index procedure

  • Pulmonary embolism (PE) or intermediate high-risk PE. 

  • Known coagulation disorders both acquired or genetic

  • Pregnant patients

  • Life expectancy <1 year due to comorbidities

  • Certain types of active cancer

  • Current participation in other clinical research studies

Updated on 14 Nov 2024. Study ID: 856271
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research